サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1487561

リウマチ治療薬市場：世界の産業分析、規模、シェア、成長、動向、2024-2034年予測

Rheumatology Therapeutics Market (Drug Class: Disease Modifying Anti-rheumatic Drugs, Nonsteroidal Anti-inflammatory Drugs, Corticosteroids, Uric Acid Drugs, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

出版日
ページ情報
英文 205 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=159.08円
リウマチ治療薬市場：世界の産業分析、規模、シェア、成長、動向、2024-2034年予測
出版日: 2024年04月02日
発行: Transparency Market Research
ページ情報: 英文 205 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

リウマチ治療薬市場- 調査範囲

TMRのリウマチ治療薬の世界市場に関する調査レポートは、2024年から2034年までの予測期間における市場の指標について貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。当レポートでは、2024年を基準年、2034年を予測年として、2018年から2034年までの世界のリウマチ治療薬市場の収益を提供しています。また、2024年から2034年までの世界のリウマチ治療薬市場の複合年間成長率（CAGR %）も掲載しています。

本レポートは広範な調査を経て作成されました。1次調査では、主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。2次調査では、主要企業の製品資料、年次報告書、プレスリリース、関連文書などを参照し、リウマチ治療薬市場を理解しました。

市場スナップショット
2023年の市場規模 488億米ドル
2034年の市場価値 651億米ドル
CAGR 2.6%

当レポートでは、世界のリウマチ治療薬市場の競合情勢について調査しています。世界のリウマチ治療薬市場で事業を展開する主要企業が特定され、各企業が様々な属性でプロファイルされています。企業概要、財務状況、最近の動向、SWOTは、本レポートで紹介されている世界のリウマチ治療薬市場におけるプレイヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 市場概要
  • 市場力学
  • 世界市場の分析と予測、2020-2034年

第5章 主要洞察

  • パイプライン分析
  • 主要製品/ブランド分析
  • 主要M&A
  • COVID-19パンデミックの業界への影響

第6章 世界市場分析と予測：薬剤クラス別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：薬剤クラス別、2020-2034年
    • 疾患修飾性抗リウマチ薬（DMARDs）
      • 合成疾患修飾性抗リウマチ薬
      • 生物学的疾患修飾性抗リウマチ薬
    • 非ステロイド性抗炎症薬（NSAIDs）
    • 副腎皮質ステロイド薬
    • 尿酸薬
    • その他
  • 市場魅力度：薬剤クラス別

第7章 世界市場分析・予測：適応疾患別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：疾患適応症別、2020-2034年
    • 関節リウマチ
    • 変形性関節症
    • 痛風
    • 乾癬性関節炎
    • 強直性脊椎炎
    • その他
  • 市場魅力度：適応疾患別

第8章 世界市場分析・予測：投与経路別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：投与経路別、2020-2034年
    • 非経口ルート
    • 経口剤
    • 外用
  • 市場魅力度：投与経路別

第9章 世界市場分析・予測：流通チャネル別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：流通チャネル別、2020-2034年
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 市場魅力度：流通チャネル別

第10章 世界市場分析・予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別、2020-2034年
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場魅力度：地域別

第11章 北米市場の分析と予測

第12章 北米市場の分析と予測欧州市場の分析と予測

第13章 アジア太平洋市場の分析と予測

第14章 ラテンアメリカ市場の分析と予測

第15章 中東・アフリカ市場の分析と予測

第16章 競合情勢

  • 市場競合マトリックス（企業階層別、企業規模別）
  • 市場シェア分析：企業別（2023年）
  • 企業プロファイル
    • F. Hoffmann-La Roche Ltd.
    • AbbVie, Inc.
    • Pfizer, Inc.
    • Takeda Pharmaceutical Company Limited
    • Amgen, Inc.
    • Genentech, Inc.
    • Novartis AG
    • Johnson & Johnson Innovative Medicine
    • Sanofi
    • Merck & Co., Inc.
図表

List of Tables

  • Table 01: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
  • Table 02: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2020-2034
  • Table 03: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
  • Table 04: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
  • Table 05: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Region, 2020-2034
  • Table 06: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country, 2020-2034
  • Table 07: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
  • Table 08: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2020-2034
  • Table 09: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
  • Table 10: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
  • Table 11: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 12: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
  • Table 13: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2020-2034
  • Table 14: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
  • Table 15: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
  • Table 16: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 17: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
  • Table 18: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2020-2034
  • Table 19: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
  • Table 20: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
  • Table 21: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 22: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
  • Table 23: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2020-2034
  • Table 24: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
  • Table 25: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034
  • Table 26: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 27: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
  • Table 28: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2020-2034
  • Table 29: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2020-2034
  • Table 30: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2020-2034

List of Figures

  • Figure 01: Global Rheumatology Therapeutics Market Size (US$ Mn), by Region, 2023 and 2034
  • Figure 02: Global Rheumatology Therapeutics Market Revenue (US$ Mn), by Drug Class, 2023
  • Figure 03: Global Rheumatology Therapeutics Market Value Share, by Drug Class, 2023
  • Figure 04: Global Rheumatology Therapeutics Market Revenue (US$ Mn), by Disease Indication, 2023
  • Figure 05: Global Rheumatology Therapeutics Market Value Share, by Disease Indication, 2023
  • Figure 06: Global Rheumatology Therapeutics Market Revenue (US$ Mn), by Route of Administration, 2023
  • Figure 07: Global Rheumatology Therapeutics Market Value Share, by Route of Administration, 2023
  • Figure 08: Global Rheumatology Therapeutics Market Revenue (US$ Mn), by Distribution Channel, 2023
  • Figure 09: Global Rheumatology Therapeutics Market Value Share, by Distribution Channel, 2023
  • Figure 10: Global Rheumatology Therapeutics Market Value Share, by Region, 2023
  • Figure 11: Global Rheumatology Therapeutics Market Value (US$ Mn) Forecast, 2020-2034
  • Figure 12: Global Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 13: Global Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2024-2034
  • Figure 14: Global Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2023 and 2034
  • Figure 15: Global Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2024-2034
  • Figure 16: Global Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 17: Global Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 18: Global Rheumatology Therapeutics Market Revenue (US$ Mn), by Distribution Channel, 2023
  • Figure 19: Global Rheumatology Therapeutics Market Value Share, by Distribution Channel, 2023
  • Figure 20: Global Rheumatology Therapeutics Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 21: Global Rheumatology Therapeutics Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 22: North America Rheumatology Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 23: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 24: North America Rheumatology Therapeutics Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 25: North America Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 26: North America Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2023 and 2034
  • Figure 27: North America Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 28: North America Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 29: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2024-2034
  • Figure 30: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2024-2034
  • Figure 31: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 32: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 33: Europe Rheumatology Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 34: Europe Rheumatology Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 35: Europe Rheumatology Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 36: Europe Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 37: Europe Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2023 and 2034
  • Figure 38: Europe Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 39: Europe Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 40: Europe Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2024-2034
  • Figure 41: Europe Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2024-2034
  • Figure 42: Europe Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 43: Europe Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 44: Asia Pacific Rheumatology Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 45: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 46: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 47: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 48: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2023 and 2034
  • Figure 49: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 50: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 51: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2024-2034
  • Figure 52: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2024-2034
  • Figure 53: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 54: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2034
  • Figure 55: Latin America Rheumatology Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 56: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 57: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 58: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 59: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2023 and 2034
  • Figure 60: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 61: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 62: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2024-2034
  • Figure 63: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2024-2034
  • Figure 64: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 65: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2024-2034
  • Figure 66: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 67: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 68: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 69: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 70: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2023 and 2034
  • Figure 71: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
  • Figure 72: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2023 and 2034
  • Figure 73: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2024-2034
  • Figure 74: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2024-2034
  • Figure 75: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
  • Figure 76: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2024-2034
目次
Product Code: TMRGL1494

Rheumatology Therapeutics Market - Scope of Report

TMR's report on the global rheumatology therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global rheumatology therapeutics market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global rheumatology therapeutics market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the rheumatology therapeutics market.

Market Snapshot
Market Value in 2023US$ 48.8 Bn
Market Value in 2034US$ 65.1 Bn
CAGR2.6%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global rheumatology therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global rheumatology therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global rheumatology therapeutics market.

The report delves into the competitive landscape of the global rheumatology therapeutics market. Key players operating in the global rheumatology therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global rheumatology therapeutics market profiled in this report.

Key Questions Answered in Global rheumatology therapeutics Market Report:

  • What is the sales/revenue generated by rheumatology therapeutics across all regions during the forecast period?
  • What are the opportunities in the global rheumatology therapeutics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Rheumatology Therapeutics Market - Research Objectives and Research Approach

The comprehensive report on the global rheumatology therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global rheumatology therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global rheumatology therapeutics market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Rheumatology Therapeutics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Rheumatology Therapeutics Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Rheumatology Therapeutics Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Class, 2020-2034
    • 6.3.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
      • 6.3.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
      • 6.3.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
    • 6.3.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • 6.3.3. Corticosteroids
    • 6.3.4. Uric Acid Drugs
    • 6.3.5. Others
  • 6.4. Market Attractiveness, by Drug Class

7. Global Rheumatology Therapeutics Market Analysis and Forecast, by Disease Indication

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Disease Indication, 2020-2034
    • 7.3.1. Rheumatoid Arthritis
    • 7.3.2. Osteoarthritis
    • 7.3.3. Gout
    • 7.3.4. Psoriatic Arthritis
    • 7.3.5. Ankylosing Spondylitis
    • 7.3.6. Others
  • 7.4. Market Attractiveness, by Disease Indication

8. Global Rheumatology Therapeutics Market Analysis and Forecast, by Route of Administration

  • 8.1. Introduction and Definitions
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Route of Administration, 2020-2034
    • 8.3.1. Parenteral Route
    • 8.3.2. Oral Route
    • 8.3.3. Topical
  • 8.4. Market Attractiveness, by Route of Administration

9. Global Rheumatology Therapeutics Market Analysis and Forecast, by Distribution Channel

  • 9.1. Introduction and Definitions
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by Distribution Channel, 2020-2034
    • 9.3.1. Hospital Pharmacy
    • 9.3.2. Retail Pharmacy
    • 9.3.3. Online Pharmacy
  • 9.4. Market Attractiveness, by Distribution Channel

10. Global Rheumatology Therapeutics Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region, 2020-2034
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness, by Region

11. North America Rheumatology Therapeutics Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Class, 2020-2034
    • 11.2.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
      • 11.2.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
      • 11.2.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
    • 11.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • 11.2.3. Corticosteroids
    • 11.2.4. Uric Acid Drugs
    • 11.2.5. Others
  • 11.3. Market Attractiveness, by Drug Class
  • 11.4. Market Value Forecast, by Disease Indication, 2020-2034
    • 11.4.1. Rheumatoid Arthritis
    • 11.4.2. Osteoarthritis
    • 11.4.3. Gout
    • 11.4.4. Psoriatic Arthritis
    • 11.4.5. Ankylosing Spondylitis
    • 11.4.6. Others
  • 11.5. Market Attractiveness, by Disease Indication
  • 11.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 11.6.1. Parenteral Route
    • 11.6.2. Oral Route
    • 11.6.3. Topical
  • 11.7. Market Attractiveness, by Route of Administration
  • 11.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 11.8.1. Hospital Pharmacy
    • 11.8.2. Retail Pharmacy
    • 11.8.3. Online Pharmacy
  • 11.9. Market Attractiveness, by Distribution Channel
  • 11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.10.1. U.S.
    • 11.10.2. Canada
  • 11.11. Market Attractiveness Analysis
    • 11.11.1. By Drug Class
    • 11.11.2. By Disease Indication
    • 11.11.3. By Route of Administration
    • 11.11.4. By Distribution Channel
    • 11.11.5. By Country

12. Europe Rheumatology Therapeutics Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Class, 2020-2034
    • 12.2.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
      • 12.2.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
      • 12.2.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
    • 12.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • 12.2.3. Corticosteroids
    • 12.2.4. Uric Acid Drugs
    • 12.2.5. Others
  • 12.3. Market Attractiveness, by Drug Class
  • 12.4. Market Value Forecast, by Disease Indication, 2020-2034
    • 12.4.1. Rheumatoid Arthritis
    • 12.4.2. Osteoarthritis
    • 12.4.3. Gout
    • 12.4.4. Psoriatic Arthritis
    • 12.4.5. Ankylosing Spondylitis
    • 12.4.6. Others
  • 12.5. Market Attractiveness, by Disease Indication
  • 12.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 12.6.1. Parenteral Route
    • 12.6.2. Oral Route
    • 12.6.3. Topical
  • 12.7. Market Attractiveness, by Route of Administration
  • 12.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 12.8.1. Hospital Pharmacy
    • 12.8.2. Retail Pharmacy
    • 12.8.3. Online Pharmacy
  • 12.9. Market Attractiveness, by Distribution Channel
  • 12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.10.1. Germany
    • 12.10.2. U.K.
    • 12.10.3. France
    • 12.10.4. Italy
    • 12.10.5. Spain
    • 12.10.6. Rest of Europe
  • 12.11. Market Attractiveness Analysis
    • 12.11.1. By Drug Class
    • 12.11.2. By Disease Indication
    • 12.11.3. By Route of Administration
    • 12.11.4. By Distribution Channel
    • 12.11.5. By Country/Sub-region

13. Asia Pacific Rheumatology Therapeutics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Class, 2020-2034
    • 13.2.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
      • 13.2.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
      • 13.2.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
    • 13.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • 13.2.3. Corticosteroids
    • 13.2.4. Uric Acid Drugs
    • 13.2.5. Others
  • 13.3. Market Attractiveness, by Drug Class
  • 13.4. Market Value Forecast, by Disease Indication, 2020-2034
    • 13.4.1. Rheumatoid Arthritis
    • 13.4.2. Osteoarthritis
    • 13.4.3. Gout
    • 13.4.4. Psoriatic Arthritis
    • 13.4.5. Ankylosing Spondylitis
    • 13.4.6. Others
  • 13.5. Market Attractiveness, by Disease Indication
  • 13.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 13.6.1. Parenteral Route
    • 13.6.2. Oral Route
    • 13.6.3. Topical
  • 13.7. Market Attractiveness, by Route of Administration
  • 13.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 13.8.1. Hospital Pharmacy
    • 13.8.2. Retail Pharmacy
    • 13.8.3. Online Pharmacy
  • 13.9. Market Attractiveness, by Distribution Channel
  • 13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.10.1. China
    • 13.10.2. Japan
    • 13.10.3. India
    • 13.10.4. Australia & New Zealand
    • 13.10.5. Rest of Asia Pacific
  • 13.11. Market Attractiveness Analysis
    • 13.11.1. By Drug Class
    • 13.11.2. By Disease Indication
    • 13.11.3. By Route of Administration
    • 13.11.4. By Distribution Channel
    • 13.11.5. By Country/Sub-region

14. Latin America Rheumatology Therapeutics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Drug Class, 2020-2034
    • 14.2.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
      • 14.2.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
      • 14.2.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
    • 14.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • 14.2.3. Corticosteroids
    • 14.2.4. Uric Acid Drugs
    • 14.2.5. Others
  • 14.3. Market Attractiveness, by Drug Class
  • 14.4. Market Value Forecast, by Disease Indication, 2020-2034
    • 14.4.1. Rheumatoid Arthritis
    • 14.4.2. Osteoarthritis
    • 14.4.3. Gout
    • 14.4.4. Psoriatic Arthritis
    • 14.4.5. Ankylosing Spondylitis
    • 14.4.6. Others
  • 14.5. Market Attractiveness, by Disease Indication
  • 14.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 14.6.1. Parenteral Route
    • 14.6.2. Oral Route
    • 14.6.3. Topical
  • 14.7. Market Attractiveness, by Route of Administration
  • 14.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 14.8.1. Hospital Pharmacy
    • 14.8.2. Retail Pharmacy
    • 14.8.3. Online Pharmacy
  • 14.9. Market Attractiveness, by Distribution Channel
  • 14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.10.1. Brazil
    • 14.10.2. Mexico
    • 14.10.3. Rest of Latin America
  • 14.11. Market Attractiveness Analysis
    • 14.11.1. By Drug Class
    • 14.11.2. By Disease Indication
    • 14.11.3. By Route of Administration
    • 14.11.4. By Distribution Channel
    • 14.11.5. By Country/Sub-region

15. Middle East & Africa Rheumatology Therapeutics Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Drug Class, 2020-2034
    • 15.2.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
      • 15.2.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
      • 15.2.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
    • 15.2.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • 15.2.3. Corticosteroids
    • 15.2.4. Uric Acid Drugs
    • 15.2.5. Others
  • 15.3. Market Attractiveness, by Drug Class
  • 15.4. Market Value Forecast, by Disease Indication, 2020-2034
    • 15.4.1. Rheumatoid Arthritis
    • 15.4.2. Osteoarthritis
    • 15.4.3. Gout
    • 15.4.4. Psoriatic Arthritis
    • 15.4.5. Ankylosing Spondylitis
    • 15.4.6. Others
  • 15.5. Market Attractiveness, by Disease Indication
  • 15.6. Market Value Forecast, by Route of Administration, 2020-2034
    • 15.6.1. Parenteral Route
    • 15.6.2. Oral Route
    • 15.6.3. Topical
  • 15.7. Market Attractiveness, by Route of Administration
  • 15.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 15.8.1. Hospital Pharmacy
    • 15.8.2. Retail Pharmacy
    • 15.8.3. Online Pharmacy
  • 15.9. Market Attractiveness, by Distribution Channel
  • 15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 15.10.1. GCC Countries
    • 15.10.2. South Africa
    • 15.10.3. Rest of Middle East & Africa
  • 15.11. Market Attractiveness Analysis
    • 15.11.1. By Drug Class
    • 15.11.2. By Disease Indication
    • 15.11.3. By Route of Administration
    • 15.11.4. By Distribution Channel
    • 15.11.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 16.2. Market Share Analysis, by Company (2023)
  • 16.3. Company Profiles
    • 16.3.1. F. Hoffmann-La Roche Ltd.
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Product Portfolio
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. SWOT Analysis
      • 16.3.1.5. Strategic Overview
    • 16.3.2. AbbVie, Inc.
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Product Portfolio
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. SWOT Analysis
      • 16.3.2.5. Strategic Overview
    • 16.3.3. Pfizer, Inc.
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Product Portfolio
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. SWOT Analysis
      • 16.3.3.5. Strategic Overview
    • 16.3.4. Takeda Pharmaceutical Company Limited
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Product Portfolio
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. SWOT Analysis
      • 16.3.4.5. Strategic Overview
    • 16.3.5. Amgen, Inc.
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Product Portfolio
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. SWOT Analysis
      • 16.3.5.5. Strategic Overview
    • 16.3.6. Genentech, Inc.
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Product Portfolio
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. SWOT Analysis
      • 16.3.6.5. Strategic Overview
    • 16.3.7. Novartis AG
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Product Portfolio
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. SWOT Analysis
      • 16.3.7.5. Strategic Overview
    • 16.3.8. Johnson & Johnson Innovative Medicine
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Product Portfolio
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. SWOT Analysis
      • 16.3.8.5. Strategic Overview
    • 16.3.9. Sanofi
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Product Portfolio
      • 16.3.9.3. Financial Overview
      • 16.3.9.4. SWOT Analysis
      • 16.3.9.5. Strategic Overview
    • 16.3.10. Merck & Co., Inc.
      • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.10.2. Product Portfolio
      • 16.3.10.3. Financial Overview
      • 16.3.10.4. SWOT Analysis
      • 16.3.10.5. Strategic Overview